AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
MiNK Therapeutics Downgraded to Market Perform by William Blair
ByAinvest
Monday, Jul 14, 2025 12:45 pm ET1min read
William Blair analyst Matthew Phipps downgraded MiNK Therapeutics (INKT) to Market Perform from Outperform on valuation grounds after the company's 700% rally. The firm cited the publication of a patient with treatment-refractory testicular cancer treated with Opdivo plus agenT-797 in the Phase I trial achieving a complete remission. MiNK shares traded up over 700% and exceeded the firm's previous fair value estimate of $33. However, the shares are now down 27% to $47.00 in premarket trading.
MiNK Therapeutics (INKT) stock experienced a significant drop on Monday, July 2, 2025, following a dramatic 700% rally on Friday, July 11, 2025. The stock traded up to $64.17 before retreating in premarket trading, down 27% to $47.00. The decline came after William Blair analyst Matthew Phipps downgraded the stock from Outperform to Market Perform on valuation grounds.The surge in MiNK Therapeutics' stock price was driven by the publication of a case report in Nature's Oncogene detailing a patient with treatment-refractory testicular cancer who achieved complete remission after treatment with Opdivo plus AGENT-797 in the company's Phase I trial [1]. The patient had previously undergone multiple unsuccessful treatments, including chemotherapy and stem cell transplant, before achieving remission with AGENT-797 combined with nivolumab.
While the clinical results were encouraging, the stock had exceeded the firm's previous fair-value estimate of $33 following Friday's rally. The downgrade comes as the analyst awaits additional data from MiNK's ongoing gastric cancer trial and clarity on how the company will secure necessary funding to expand its pipeline [2].
MiNK ended the first quarter with only $3.2 million in cash, raising concerns about its ability to fund ongoing research without additional capital. The company's market capitalization now stands at $255.76 million [3].
References:
[1] https://www.oncologypipeline.com/apexonco/how-mink-stole-nk-t-show
[2] https://www.investing.com/news/analyst-ratings/william-blair-downgrades-mink-therapeutics-stock-to-market-perform-after-700-surge-93CH-4133706
[3] https://finance.yahoo.com/news/mink-therapeutics-stock-falls-william-120438127.html
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet